[go: up one dir, main page]

IT201700057635A1 - Composizione per uso nel trattamento dei sintomi extra-esofagei del reflusso gastrico - Google Patents

Composizione per uso nel trattamento dei sintomi extra-esofagei del reflusso gastrico

Info

Publication number
IT201700057635A1
IT201700057635A1 IT102017000057635A IT201700057635A IT201700057635A1 IT 201700057635 A1 IT201700057635 A1 IT 201700057635A1 IT 102017000057635 A IT102017000057635 A IT 102017000057635A IT 201700057635 A IT201700057635 A IT 201700057635A IT 201700057635 A1 IT201700057635 A1 IT 201700057635A1
Authority
IT
Italy
Prior art keywords
esophageic
symptoms
extra
treatment
composition
Prior art date
Application number
IT102017000057635A
Other languages
English (en)
Inventor
Luigi Mercuri
Original Assignee
Drugs Minerals And Generics Italia S R L In Forma Abbreviata D M G Italia S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Drugs Minerals And Generics Italia S R L In Forma Abbreviata D M G Italia S R L filed Critical Drugs Minerals And Generics Italia S R L In Forma Abbreviata D M G Italia S R L
Priority to IT102017000057635A priority Critical patent/IT201700057635A1/it
Priority to EP18730122.1A priority patent/EP3630064A1/en
Priority to US16/617,368 priority patent/US20200085854A1/en
Priority to PE2019002445A priority patent/PE20200526A1/es
Priority to MX2019013917A priority patent/MX2019013917A/es
Priority to UAA201911978A priority patent/UA126580C2/uk
Priority to PCT/IB2018/053514 priority patent/WO2018215897A1/en
Priority to MA048955A priority patent/MA48955A/fr
Priority to EA201992743A priority patent/EA201992743A1/ru
Publication of IT201700057635A1 publication Critical patent/IT201700057635A1/it
Priority to MX2022015182A priority patent/MX2022015182A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/734—Alginic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IT102017000057635A 2017-05-26 2017-05-26 Composizione per uso nel trattamento dei sintomi extra-esofagei del reflusso gastrico IT201700057635A1 (it)

Priority Applications (10)

Application Number Priority Date Filing Date Title
IT102017000057635A IT201700057635A1 (it) 2017-05-26 2017-05-26 Composizione per uso nel trattamento dei sintomi extra-esofagei del reflusso gastrico
EP18730122.1A EP3630064A1 (en) 2017-05-26 2018-05-18 Composition for use in the treatment of extraoesophageal gastric reflux symptoms
US16/617,368 US20200085854A1 (en) 2017-05-26 2018-05-18 Composition for use in the treatment of extraoesophageal gastric reflux symptoms
PE2019002445A PE20200526A1 (es) 2017-05-26 2018-05-18 Composicion para uso en el tratamiento de sintomas de reflujo gastrico extraoesofagico
MX2019013917A MX2019013917A (es) 2017-05-26 2018-05-18 Composicion para usarse en el tratamiento de sintomas de reflujo gastrico extraoesofagico.
UAA201911978A UA126580C2 (uk) 2017-05-26 2018-05-18 Застосування композиції, що містить альгінову та гіалуронову кислоти, для лікування екстраезофагеальних симптомів шлункового рефлюксу
PCT/IB2018/053514 WO2018215897A1 (en) 2017-05-26 2018-05-18 Composition for use in the treatment of extraoesophageal gastric reflux symptoms
MA048955A MA48955A (fr) 2017-05-26 2018-05-18 Composition destinée à être utilisée dans le traitement des symptômes du reflux gastrique extra- sophagien
EA201992743A EA201992743A1 (ru) 2017-05-26 2018-05-18 Композиция для применения при лечении экстраэзофагеальных симптомов желудочного рефлюкса
MX2022015182A MX2022015182A (es) 2017-05-26 2019-11-21 Composicion para usarse en el tratamiento de sintomas de reflujo gastrico extraesofagico.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102017000057635A IT201700057635A1 (it) 2017-05-26 2017-05-26 Composizione per uso nel trattamento dei sintomi extra-esofagei del reflusso gastrico

Publications (1)

Publication Number Publication Date
IT201700057635A1 true IT201700057635A1 (it) 2018-11-26

Family

ID=60294045

Family Applications (1)

Application Number Title Priority Date Filing Date
IT102017000057635A IT201700057635A1 (it) 2017-05-26 2017-05-26 Composizione per uso nel trattamento dei sintomi extra-esofagei del reflusso gastrico

Country Status (9)

Country Link
US (1) US20200085854A1 (it)
EP (1) EP3630064A1 (it)
EA (1) EA201992743A1 (it)
IT (1) IT201700057635A1 (it)
MA (1) MA48955A (it)
MX (2) MX2019013917A (it)
PE (1) PE20200526A1 (it)
UA (1) UA126580C2 (it)
WO (1) WO2018215897A1 (it)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005105167A1 (de) * 2004-04-16 2005-11-10 Cellmed Ag Injizierbare vernetzte und unvernetzte alginate und ihre verwendung in der medizin und in der ästhetischen chirurgie
WO2009064617A1 (en) * 2007-11-14 2009-05-22 S.K. Pharmaceuticals, Inc. Stabilized glycosaminolglycan preparations and related methods
US20110097367A1 (en) * 2008-01-16 2011-04-28 Cellmed Ag Monolithic in-situ cross-linked alginate implants
EP2545925A1 (en) * 2011-07-12 2013-01-16 Holy Stone Healthcare Co.,Ltd. Compositions comprising hyaluronic acid for treating and preventing mucosa related diseases
WO2018044673A1 (en) * 2016-08-31 2018-03-08 Pharmunion, LLC A nutritional composition of pharmaceutical and dietary supplement containing said nutritional of pharmaceutical composition

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201600121601A1 (it) * 2016-11-30 2018-05-30 Nekkar Lab Srl Composizione orale per il trattamento del reflusso gastroesofageo e del reflusso laringo-faringeo

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005105167A1 (de) * 2004-04-16 2005-11-10 Cellmed Ag Injizierbare vernetzte und unvernetzte alginate und ihre verwendung in der medizin und in der ästhetischen chirurgie
WO2009064617A1 (en) * 2007-11-14 2009-05-22 S.K. Pharmaceuticals, Inc. Stabilized glycosaminolglycan preparations and related methods
US20110097367A1 (en) * 2008-01-16 2011-04-28 Cellmed Ag Monolithic in-situ cross-linked alginate implants
EP2545925A1 (en) * 2011-07-12 2013-01-16 Holy Stone Healthcare Co.,Ltd. Compositions comprising hyaluronic acid for treating and preventing mucosa related diseases
WO2018044673A1 (en) * 2016-08-31 2018-03-08 Pharmunion, LLC A nutritional composition of pharmaceutical and dietary supplement containing said nutritional of pharmaceutical composition

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; April 2017 (2017-04-01), ARAGONA S E ET AL: "Regenerative medicine in the treatment of gastro-esophageal reflux disease and laryngo-pharyngeal reflux. From research to cure.", XP002779043, Database accession no. NLM28702984 *
JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, vol. 31, no. 2 Suppl. 2, April 2017 (2017-04-01), pages 207 - 212, ISSN: 0393-974X *

Also Published As

Publication number Publication date
PE20200526A1 (es) 2020-03-09
US20200085854A1 (en) 2020-03-19
MA48955A (fr) 2020-04-08
EP3630064A1 (en) 2020-04-08
EA201992743A1 (ru) 2020-03-13
WO2018215897A1 (en) 2018-11-29
MX2022015182A (es) 2023-01-30
MX2019013917A (es) 2020-07-28
UA126580C2 (uk) 2022-11-02

Similar Documents

Publication Publication Date Title
LTC3057969I2 (lt) Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su kit
HUE064141T2 (hu) Azolopirimidin rákkal összefüggõ rendellenességek kezelésére
LT3882250T (lt) Tetrahidropiranilamino-pirolopirimidinonas, skirtas panaudoti btk nulemtų sutrikimų gydymui
IL247841A0 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
LT3661514T (lt) Mavakamtenas, skirtas naudoti gydant hipertrofinę kardiomiopatiją
EP3370703A4 (en) GEMCABEN COMBINATIONS FOR TREATING HEART CIRCULATION DISEASES
LT3472153T (lt) Pirimidin-2-ilamino-1h-pirazolai kaip lrrk2 inhibitoriai, skirti naudoti neurodegeneracinių sutrikimų gydyme
PL3936130T3 (pl) Schemat dawkowania walbenazyny w leczeniu hiperkinetycznych zaburzeń ruchu
CL2015002897A1 (es) Inhibidores de bace1
IT201600101413A1 (it) Composizione liquida per uso nel trattamento del reflusso gastroesofageo
PL3978074T3 (pl) Terlipresyna do leczenia zespołu wątrobowo-nerkowego typu 1
IT201600121601A1 (it) Composizione orale per il trattamento del reflusso gastroesofageo e del reflusso laringo-faringeo
LT3687567T (lt) Anti-adrenomedulino rišiklis, skirtas panaudoti taikant ligos simptomų terapiją arba profilaktiką
HUE058314T2 (hu) Pridopidin alkalmazása Rett-szindróma kezelésére
PL3732294T3 (pl) Tymohydrochinon do stosowania w leczeniu hiperglikemii
PL4101454T3 (pl) Kompozycje do stosowania w leczeniu nadciśnienia
IT201600121617A1 (it) Composizione per il trattamento del reflusso gastroesofageo
HUE056798T2 (hu) Imatinib stroke kezelésében való alkalmazásra
DK3096775T3 (da) SOCS-mimetika til behandling af sygdomme
HUE058645T2 (hu) Gyógyszer köszvény kezelésében való felhasználásra
LT3405197T (lt) Delgocitinibo panaudojimas lėtinės rankų egzemos gydymui
HUE046209T2 (hu) Kompozíció porckoronggal összefüggõ fájdalom kezelésében történõ alkalmazásra
EP3634387C0 (en) LOW TABLE DOSAGE FORM
IT201700111939A1 (it) Composizione farmaceutica per l’uso nel trattamento di stati infiammatori
PL3285791T3 (pl) Kompozycja do leczenia gardła/jamy gardłowej